NCT06121232

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn if a process called neuromodulation can help to improve pain due to CIP

Detailed description

Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds * Patients seen at Pain Management Center at MD Anderson Cancer Center * Patient ages greater or equal to 18 years but less than or equal to 85 years Exclusion Criteria: * Patients with cognitive dysfunction * Patient with recent history (\<6 months) of drug or alcohol abuse * Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection * Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy

Conditions

• Neuropathy;Peripheral

Interventions

Type	Name	Description
DEVICE	Abbott® DRG / Abbott®/Medtronic® SCS	Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
OTHER	Control Group	Participants will not receive any intervention

Timeline

• Start date: 2023-11-02
• Primary completion: 2026-04-01
• Completion: 2026-04-01
• First posted: 2023-11-07
• Last updated: 2025-11-17

Locations

1 site across 1 country: United States